Ollin Biosciences raises $330M Series B for eye disease drug trials

June 24, 2026 7:01 AM

Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company founded in 2023, has closed an oversubscribed $330 million Series B financing round ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found